<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04956926</url>
  </required_header>
  <id_info>
    <org_study_id>JS201-001-I</org_study_id>
    <nct_id>NCT04956926</nct_id>
  </id_info>
  <brief_title>Clinical Study of JS201 in Patients With Advanced Malignant Tumors</brief_title>
  <official_title>An Open-label, First-in-human, Dose Escalation and Expansion Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of JS201 in Patients With Advanced Malignant Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Junshi Bioscience Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Junshi Bioscience Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, phase I clinical study to evaluate the safety, tolerability,&#xD;
      pharmacokinetic (PK) profile, pharmacodynamic (PD) profile, immunogenicity and preliminary&#xD;
      efficacy of JS201 in the patients with advanced malignant tumors who have progression after&#xD;
      or on the standard of care, or no effective standard therapeutic regimen. This study is&#xD;
      divided into three periods: dose-escalation period, dose expansion period, and clinical&#xD;
      expansion period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2021</start_date>
  <completion_date type="Anticipated">July 7, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 7, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with DLT (Dose limiting Toxicity)</measure>
    <time_frame>21 days after first infusion of study drug</time_frame>
    <description>DLT is defined as any of the specified toxicities evaluated as at least possibly related with the study drug within 21 days after the first dose (NCI-CTCAE v5.0);</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects with adverse event (AE)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>An Adverse Event (AE) is defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects with serious adverse event (SAE)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>A Serious Adverse Event (SAE) is an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects with immune related adverse event (irAE)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>IrAE is assessed according to the judgement of investigators</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>anti-drug body (ADA)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>incidence of anti-drug body (ADA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peak concentration (Cmax)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Cmax after JS201 administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>trough concentration (Ctrough)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Ctrough after JS201 administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the plasma drug concentration-time curve (AUC0-t )</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>AUC0-t after JS201 administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>volume of distribution (Vss)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Vss after JS201 administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>elimination half-life (t1/2)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>t1/2 after JS201 administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clearance rate (CL)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>CL after JS201 administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The efficacy evaluated by the investigator in accordance with RECIST 1.1 criteria (solid tumors) or Lugano criteria (2014, lymphoma), including complete response (CR) and partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>DOR is defined as the time from the date of the first documentation of response (confirmed CR or confirmed PR) to the date of the first documentation of PD or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The efficacy evaluated by the investigator in accordance with RECIST 1.1 criteria (solid tumors) or Lugano criteria (2014, lymphoma), including CR, PR and stable disease (SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>PFS is defined as the time from the date of randomization to the earlier of the dates of the first documentation of progressive disease or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>OS is defined as the time from the date of randomization to the date of death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">174</enrollment>
  <condition>Patients With Advanced Malignant Tumors</condition>
  <arm_group>
    <arm_group_label>JS201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JS201</intervention_name>
    <description>JS201 is administered intravenously Q3W at the corresponding dose.</description>
    <arm_group_label>JS201</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        1. Understanding and voluntarily signing the informed consent form; 2. Male or female, aged&#xD;
        18 to 70 years (inclusive), for the dose-expansion and clinical expansion parts, aged 18 to&#xD;
        75 years (inclusive); 3. Patients with histologically or cytologically confirmed advanced&#xD;
        malignant tumors who have progression after or on the standard of care, or have no&#xD;
        effective standard therapeutic regimen; 4. ECOG PS score: 0~1; 5. Patients with life&#xD;
        expectancy ≥12 weeks; 6. Presence of at least one measurable lesion meeting the&#xD;
        requirements in RECIST v1.1 (solid tumors) or 2014 Lugano (lymphoma) evaluation criteria;&#xD;
        7. Agreement on providing fresh biopsied sample before treatment, or archived sample within&#xD;
        two years if there is unreasonable risk of biopsy to the patient; 8. Adequate function of&#xD;
        vital organs; 9. Female patients at childbearing age, as well as the male patients whose&#xD;
        partners are women of childbearing potential, are required to use a medically recognized&#xD;
        contraceptive measure (e.g., intrauterine device IUD, contraceptive or condom) during the&#xD;
        study and within 3 months after the end of study treatment; the serum HCG test must be&#xD;
        negative in the female patients at childbearing age within 7 days prior to enrollment; and&#xD;
        the female patients must be not lactating; Exclusion criteria&#xD;
&#xD;
          1. Known allergy to any component of JS201;&#xD;
&#xD;
          2. Having received the treatment targeting TGF-β or TGF-βreceptor previously;&#xD;
&#xD;
          3. Not receiving other investigational product within 4 weeks prior to the first dose of&#xD;
             JS201;&#xD;
&#xD;
          4. Major surgery or in the recovery period of the surgery within 4 weeks prior to the&#xD;
             first dose of JS201.&#xD;
&#xD;
          5. Antitumor chemotherapy, radiotherapy, hormone therapy, targeted therapy, immunotherapy&#xD;
             or biotherapy within 4 weeks prior to the first dose of JS201;&#xD;
&#xD;
          6. Use of immunosuppressive drug or immunostimulants within two weeks prior to the first&#xD;
             dose of JS201;&#xD;
&#xD;
          7. Vaccination of live attenuated vaccine within 30 days prior to the first dose of&#xD;
             JS201; use of seasonal influenza vaccine free of live virus is allowed;&#xD;
&#xD;
          8. Having other malignant tumor other than the disease investigated within 5 years prior&#xD;
             to the first dose of JS201, however, except for the malignant tumors that can be&#xD;
             expected to be cured after treatment (including but not limited to sufficiently&#xD;
             treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell carcinoma&#xD;
             of skin, or ductal carcinoma in situ treated with radical surgery);&#xD;
&#xD;
          9. Symptomatic central nervous system (CNS) metastasis requiring intervention (including&#xD;
             corticosteroids and antiepileptics).&#xD;
&#xD;
         10. Active autoimmune disease requiring systemic therapy (e.g., use of disease-modifying&#xD;
             drugs, corticosteroids or immunosuppressants) within two years prior to the first dose&#xD;
             of JS201.&#xD;
&#xD;
         11. Active infection requiring systematic treatment/antibiotics or intravenous use of&#xD;
             systemic anti-infection therapy with one week prior to the first dose;&#xD;
&#xD;
         12. History of concurrent serious cerebro- and cardiovascular diseases;&#xD;
&#xD;
         13. Presence of active tuberculosis, or interstitial lung disease requiring oral or&#xD;
             intravenous steroids or history of pneumonia;&#xD;
&#xD;
         14. Known positive for human immunodeficiency virus (HIV);&#xD;
&#xD;
         15. Having evidence on infection of hepatitis B virus (HBV) or hepatitis C virus (HCV);&quot;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pan He, Postgraduate</last_name>
    <phone>+8615172333540</phone>
    <email>pan_he@junshipharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Zhang, Prof</last_name>
      <email>zhangli@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 23, 2021</study_first_submitted>
  <study_first_submitted_qc>July 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2021</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

